ABCSG 36/Penelope summary
Phase-III-study evaluating palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormonereceptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy.
|Start:||12/2013, national: 12/2014|
|Coordinating investigator:||Gnant, Michael; Wien|
Link for studyteam-members only
Further information about this trial
Access to these informations only with keyword. If required, please ask the responsible project manager.